Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02317276 · ClinicalTrials.gov registry record · Phase 4
A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal
A Phase 4 study, sponsored by University of California, San Francisco.
- Terminated
- Registry status
- Phase 4
- Development phase
- 11
- Enrollment target
NCT02317276 is a Phase 4 study that was terminated before completion, run by University of California, San Francisco. The registered enrollment target is 11 participants.
The verdict
NCT02317276, a Phase 4 study, was terminated before completion, sponsored by University of California, San Francisco.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the differential expression of AD biomarkers in serum, plasma, and skin biopsies from both lesional and non-lesional skin in moderate to severe AD patients in the presence of TCS and after withdrawal from TCS.
Interventions
- DRUG Triamcinolone 0.1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2014-12 |
| Est. Completion | 2017-04-06 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02317276
The ClinicalTrials.gov registry entry for NCT02317276 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Triamcinolone 0.1% is the first listed.
NCT02317276 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02317276 about?
NCT02317276 is a clinical study titled "A Study to Determine Serum and Skin Biopsy Biomarkers in Patients Receiving Topical Corticosteroid (TCS) and Following TCS Withdrawal". The purpose of this study is to assess the differential expression of AD biomarkers in serum, plasma, and skin biopsies from both lesional and non-lesional skin in moderate to severe AD patients in the presence of TCS and after withdrawal from TCS.
What is the current status of trial NCT02317276?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2014-12. Estimated completion is 2017-04-06.
What interventions are being tested in trial NCT02317276?
The interventions under investigation include: Triamcinolone 0.1% (DRUG).
Who is sponsoring clinical trial NCT02317276?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.